Blood transcriptomic biomarkers of Alzheimer's disease patients treated with EHT 0202

Journal of Alzheimer's Disease

Volumn 34, Issue 2, 2013, Pages 469-483

  Désiré, Laurent ^a   Blondiaux, Elodie ^b   Carrière, Jennifer ^a   Haddad, Raphael ^a   Sol, Olivier ^a   Fehlbaum Beurdeley, Pascale ^a   Einstein, Rich ^a   Zhou, Weiyin ^a   Pando, Matthew P ^a  

^a Exonhit SA   (France)

^b Effi Stat   (France)

Author keywords

Alzheimer's disease; biomarker; blood; drug response; gene expression; microarray; molecular signature; transcriptome

Indexed keywords

DONEPEZIL; EHT 0202; GALANTAMINE; NOOTROPIC AGENT; PLACEBO; RIVASTIGMINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ARTICLE; BIOLOGICAL MONITORING; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MARKER GENE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TRANSCRIPTOMICS; TREATMENT RESISTANT DEPRESSION;

EID: 84874301925     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121501     Document Type: Article

References (51)

1. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 4487-4498
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (Pubitemid 14076461)
3. Cummings JL, Doody R, Clark C (2007) Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology 69, 1622-1634 (Pubitemid 350287147)
4. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E (2006) The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 20, 6-15 (Pubitemid 44356888)
5. Baine MJ, Chakraborty S, Smith LM, Mallya K, Sasson AR, Brand RE, Batra SK (2011) Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One 6, e17014
6. Sharp FR, Xu H, Lit L, Walker W, Apperson M, Gilbert DL, Glauser TA, Wong B, Hershey A, Liu DZ, Pinter J, Zhan X, Liu X, Ran R (2006) The future of genomic profiling of neurological diseases using blood. Arch Neurol 63, 1529-1536 (Pubitemid 44748794)
7. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 104, 955-960 (Pubitemid 46154718)
8. Grunblatt E, Bartl J, Zehetmayer S, Ringel TM, Bauer P, Riederer P, Jacob CP (2009) Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis 16, 627-634
9. Maes OC, Xu S, Yu B, Chertkow HM,Wang E, Schipper HM (2007) Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 28, 1795-1809 (Pubitemid 47539691)
10. Booij BB, Lindahl T,Wetterberg P, SkaaneNV, Sæbø S, Feten G, Rye PD, Kristiansen LI, Hagen N, Jensen M, Bardsen K, Winblad B, Sharma P, L?onneborgA(2011)Agene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis 23, 109-119
11. Sullivan PF, Fan C, Perou CM (2006) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141, 261-268
12. Borroni B, Colciaghi F, Pastorino L, Pettenati C, Cottini E, Rozzini L, Monastero R, Lenzi GL, Cattabeni F, Di Luca M, Padovani A (2001) Amyloid precursor protein in platelets of patients with Alzheimer disease: Effect of acetylcholinesterase inhibitor treatment. Arch Neurol 58, 442-446 (Pubitemid 32217461)
13. Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D, Carriére J, Guihal C, Soucaille C, Rouet F, Drouin D, Sol O, Jordan H, Wu D, Lei L, Einstein R, Schweighoffer F, Bracco L (2010) Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression. Alzheimers Dement 6, 25-38
14. Zhou W, Jordan H, Brenner M, Johnson S, Wu D, Lei L, Pallares D, Beurdeley P, Rouet F, Gill PS, Bracco L, Soucaille C, Einstein R (2009) High resolution analysis of the human transcriptome: Detection of extensive alternative splicing independent of transcriptional activity. BMC Genet 10, 63-73
15. Nilsen TW, Graveley BR (2010) Expansion of the eukaryotic proteome by alternative splicing. Nature 463, 457-463
16. TwineNA, Janitz K,WilkinsMR,JanitzM(2011) Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease. PLoS One 6, e16266
17. Miller JA, Horvath S, Geschwind DH (2010) Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Proc Natl Acad Sci U S A 107, 12698-12703
18. Avramopoulos D, Szymanski M, Wang R, Bassett S (2010) Gene expression reveals overlap between normal aging and Alzheimer's disease genes. Neurobiol Aging 32, 2319.e27-e34
19. Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, Schweighoffer F, Desire L (2008) Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 106, 392-404 (Pubitemid 351840218)
20. Drott J, Desire L, Drouin D, Pando M, Haun F (2010) Etazolate improves performance in a foraging and homing task in aged rats. Eur J Pharmacol 634, 95-100
21. Liskowsky W, Schliebs R (2006) Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 24, 149-156 (Pubitemid 43294621)
22. Vellas B, Sol O, Snyder PJ, Ousset PJ, Haddad R, Maurin M, Lemarie JC, Desire L, Pando MP EHT0202/002 study group (2011), EHT0202 in Alzheimer's disease: A 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 8, 203-212
23. Calciano MA, Zhou W, Snyder PJ, Einstein R (2010) Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells. Alzheimers Dement 5, 386-393
24. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc 4, 44-57
25. Guy W (1976) Early Clinical Drug Evaluation (ECDEU) assessment manual for psychopharmacology. National Institute of Mental Health, Publication Number 76-336. Rockville, USA
26. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A 101, 2070-2075 (Pubitemid 38229016)
27. Luchsinger JA, Gustafson DR (2009) Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16, 693-704
28. Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490, 97-113 (Pubitemid 38482164)
29. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348, 1215-1222 (Pubitemid 36359297)
30. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S (2007) Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology 68, 1902-1908 (Pubitemid 46848622)
31. Serneels L,Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, Van Houtvin T, Esselmann H, Paul S, Schafer MK, Berezovska O, Hyman BT, Sprangers B, Sciot R, Moons L, Jucker M, Yang Z, May PC, Karran E, Wiltfang J, D' Hooge R, De Strooper B (2009) gamma-Secretase heterogeneity in the Aph1 subunit: Relevance for Alzheimer's disease. Science 324, 639-642
32. Asai M, Yagishita S, Iwata N, Saido TC, Ishiura S, Maruyama K(2011)Analternative metabolic pathway of amyloid precursor protein C-terminal fragments via cathepsin B in a human neuroglioma model. FASEB J 25, 3720-3730
33. Akuffo EL, Davis JB, Fox SM, Gloger IS, Hosford D, Kinsey EE, Jones NA, Nock CM, Roses AD, Saunders AM, Skehel JM, Smith MA, Cutler P (2008) The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 13, 618-636
34. Pasinetti GM (2001) Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia. J Neurosci Res 65, 71-76
35. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114, 1624-1634 (Pubitemid 40385553)
36. Soderling T (2000) CaM-kinases: Modulators of synaptic plasticity. Curr Opin Neurobiol 10, 375-380 (Pubitemid 30389306)
37. Crews L, Masliah E (2010) Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 19(R1), R12-R20
38. Salminen A, Kaarniranta K, Haapasalo A, Soininen H, HiltunenM(2011) AMP-activated protein kinase:Apotential player in Alzheimer's disease. AMP-activated protein kinase: A potential player in Alzheimer's disease. J Neurochem 118, 460-474
39. Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ, Barci BM, Torrey EF (2007) Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci 31, 221-243 (Pubitemid 47338416)
40. HiggsBW, ElashoffM, Richman S, Barci B (2006) An online database for brain disease research. BMC Genomics 7, 70
41. Pavlidis P, Noble WS (2001) Analysis of strain and regional variation in gene expression in mouse brain. Genome Biology 2, RESEARCH0042.1-0042.15
42. Cho H, Lee JK (2001) Bayesian hierarchical error model for analysis of gene expression data. Bioinformatics 20, 2016-2025
43. Iacobas DA, Urban M, Iacobas S, Spray DC (2003) Control and variability of gene expression in mouse brain and in a neuroblastoma cell line. Rom J Physiol 39-40, 71-90
44. Johnstone D, Milward EA, Berretta R, Moscato P, Alzheimer's Disease Neuroimaging Initiative (2012) Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One 7, e34341
45. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050 (Pubitemid 44684524)
46. TwineNA, Janitz K,WilkinsMR,JanitzM(2011) Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease. PLoS One 6, e16266
47. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes G, Trepicchio WL, Strahs A, Immermann F, Slonim DK, Dorner AJ (2005) Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 11, 1181-1189 (Pubitemid 40175769)
48. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T (2008) Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology 47, 780-788 (Pubitemid 351796361)
49. Rezai-Zadeh K, Gate D, Szekely CA, Town T (2009) Can peripheral leukocytes be used as Alzheimer's disease biomarkers? Expert Rev Neurother 9, 1623-1633
50. Biron KE, Dickstein DL, Gopaul R, Jefferies WA (2011) Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One 6, e23789
51. Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreasen N, Grundke-Iqbal I, Iqbal K (2011) Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. J Alzheimers Dis 25, 505-515